Education and Training
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: PLN-74809
- radiation: Knottin tracer
Eligibility
Inclusion Criteria:
- Diagnosis of IPF, within 5 years prior to Screening,
- FVC %predicted ≥45%; historical FVC for entry in the study is permitted if within 1
month of screening.
- DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted
if within 1 month of screening.
- Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if
on a stable dose for at least 3 months
Exclusion Criteria:
- Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
not approved for that indication by the FDA
- Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
ratio <0.7
- Clinical evidence of active infection, including but not limited to bronchitis,
pneumonia, sinusitis that can affect FVC measurement or IPF progression
- Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
of Screening
- Smoking of any kind within 3 months of Screening
Ages Eligible for Study
40 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joshua Mooney, MD
Not Recruiting